A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers
The current study represents the first report to evaluate a CD40 agonist antibody in combination with concurrent chemoradiation in the neoadjuvant setting for patients with esophageal/GEJ cancers. This novel strategy was both safe and feasible, producing encouraging path CR rates that compare favorably with historical data. Our findings support the further evaluation of how immune-based therapies may be incorporated into perioperative treatment paradigms for upper gastrointestinal malignancies.
Authors
- Bridget P. Keenan (ORCID: https://orcid.org/0000-0001-6075-489X)
- Joseph Chao (ORCID: https://orcid.org/0000-0002-1809-504X)
- Andrew Ko (ORCID: https://orcid.org/0000-0003-0426-1753)
- Autumn J. McRee
- Paul E. Oberstein (ORCID: https://orcid.org/0000-0001-5918-6004)
- Veena Shankaran (ORCID: https://orcid.org/0000-0001-8136-6140)
- Aaron J. Scott (ORCID: https://orcid.org/0000-0002-0301-3072)
- Xiaodong Yang
- Frank J. Hsu
- Marcus Smith Noel (ORCID: https://orcid.org/0000-0002-3658-6950)
- Erin L. Filbert (ORCID: https://orcid.org/0000-0001-5077-9030)
- Davendra Sohal (ORCID: https://orcid.org/0000-0002-0182-8403)
- Caio Max Sao Pedro Rocha Lima
- Mary Crow
- Lawrence H. Fong (ORCID: https://orcid.org/0000-0002-6428-428X)
Institutions
- University of North Carolina at Chapel Hill (US)
- Atrium Health Wake Forest Baptist (US)
- Johnson & Johnson (United States) (US)
- University of Arizona (US)
- University of California, San Francisco (US)
- Georgetown University (US)
- University of Washington (US)
- NYU Langone Health (US)
- City of Hope (US)
- Apexigen (United States) (US)
- Boston Public Schools (US)
- Texas Orthopedic Hospital (US)
- Wake Forest Baptist Comprehensive Cancer Center
- University of Arizona Cancer Center
- University of Cincinnati (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0513
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18